( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.
Global Veterinary Therapeutics Market Growth is driven by advancements in veterinary medicine, increasing pet humanization, and rising demand for disease management solutions.Pune, Jan. 30, 2025 ...